ABL001
Phase 1Small molecule
NovartisABL001 is one of 12 small molecule programs targeting Blinatumomab. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Blinatumomab
#DrugCompanyPhaseTrials
1Blincyto
AmgenPhase 2
Trexall
Jazz PharmaceuticalsPhase 2
Cytosar
TevaPhase 2
Venclexta
AbbViePhase 2
Oncaspar
SServier
Phase 2
Besponsa
WWyeth-Lederle Vaccines
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Rayos
RRoxane Laboratories
Phase 1
Revuforj
SSyndax Pharmaceuticals
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABL001. EMBL-EBI & Wellcome Sanger Institute.
- [4]